CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 117 enrolled
Drug / intervention
PF-06291874 +1 moredrug
Likely dose
PF-06291874 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01856595
NCT01856595Phase 1Completed
CompareCT.gov

A Phase 1, Placebo-controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Escalating Oral Doses Of Pf-06291874 In Adults With Type 2 Diabetes Mellitus

Pfizer·interventional·Posted May 17, 2013·Updated Nov 1, 2018

In Brief

A Phase 1 clinical trial evaluating PF-06291874 and Placebo for Diabetes Mellitus, Type 2. Completed, enrolled 117 participants across 3 sites.

Detailed Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of PF-06291874 in Type 2 Diabetes patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMay 17, 2013
Enrollment StartMay 13, 2013
Primary CompletionJan 10, 2014
Study CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 13.1 years ago

Interventions

PF-06291874drug

The dosing schedule is 5, 15, 50, 100 and 150 mg QD for 14 days for the first 5 cohorts in Part A. The dosing schedule for the first cohort in Part B is 15 mg QD for 14 days and 30 mg QD for 28 days

Placebodrug

Placebo tablets will be administered QD in each of the cohorts for 14 days (Part A cohorts 1- 5 and Part B cohort 1) or 28 days (Part B cohort 2).